Pazopanib in advanced and platinum-resistant urothelial cancer: an open-label, single group, phase 2 trialAndrea Necchi, Roberto Salvioni, Carlo Morosi et al.|The Lancet Oncology|2012Cited by 145
Targeted prostate cancer screening in men with mutations in <i>BRCA1</i> and <i>BRCA2</i> detects aggressive prostate cancer: preliminary analysis of the results of the IMPACT studyAnita Mitra, Alison Falconer, Elizabeth Bancroft et al.|British Journal of Urology|2010Cited by 98
A prospective prostate cancer screening programme for men with pathogenic variants in mismatch repair genes (IMPACT): initial results from an international prospective studyElizabeth Bancroft, Alan Donaldson, Elizabeth Page et al.|The Lancet Oncology|2021Cited by 93